14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
Poolbeg Pharma plc (POLB.L) RNA sequencing ahead of pioneering AI analysis programme
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global
GlaxoSmithKline plc (LSE/NYSE:GSK) Trelegy Ellipta: positive opinion from CHMP Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion